Home / Resource Library / Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA

Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA

Study compared the use of obinutuzumab versus rituximab for treatment of younger patients with diffuse large b cell lymphoma. (Abstract)